Literature DB >> 25228725

Identification and treatment of APS renal involvement.

M G Tektonidou1.   

Abstract

Renal involvement in antiphospholipid syndrome (APS), either primary or systemic lupus erythematosus (SLE)-related APS, includes renal artery stenosis or thrombosis, renal infarction, renal vein thrombosis and a small-vessel vaso-occlusive nephropathy defined as "antiphospholipid antibody (aPL)-associated nephropathy." aPL-associated nephropathy is characterized by acute lesions, thrombotic microangiopathy, and chronic lesions such as fibrous intimal hyperplasia, organizing thrombi with or without recanalization, fibrous occlusions of arteries or arterioles and focal cortical atrophy. Systemic hypertension, hematuria, proteinuria (ranging from mild to nephrotic level) and renal insufficiency represent the major clinical manifestations associated with aPL-associated nephropathy. Similar renal histologic and clinical characteristics have been described among all different groups of patients with positive aPL (primary APS, SLE-related APS, catastrophic APS and SLE/non-APS with positive aPL). In patients with aPL-associated nephropathy lesions in the absence of other causes associated with similar histological characteristics, aPL testing needs to be considered.
© The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  Antiphospholipid syndrome; antiphospholipid antibody-associated nephropathy; renal manifestations; thrombotic microangiopathy

Mesh:

Substances:

Year:  2014        PMID: 25228725     DOI: 10.1177/0961203314538687

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  11 in total

Review 1.  Vascular Manifestations in Antiphospholipid Syndrome (APS): Is APS a Thrombophilia or a Vasculopathy?

Authors:  Salma Siddique; Jessie Risse; Guillaume Canaud; Stéphane Zuily
Journal:  Curr Rheumatol Rep       Date:  2017-09-04       Impact factor: 4.592

2.  Renal vein thrombosis complicating severe acute pyelonephritis with renal abscesses and associated bacteraemia caused by extended-spectrum beta-lactamase producing Escherichia coli.

Authors:  Stelios F Assimakopoulos; Pantelis Kraniotis; Charalambos Gogos; Markos Marangos
Journal:  CEN Case Rep       Date:  2018-01-11

Review 3.  Current treatment of antiphospholipid syndrome: lights and shadows.

Authors:  Gerard Espinosa; Ricard Cervera
Journal:  Nat Rev Rheumatol       Date:  2015-06-30       Impact factor: 20.543

4.  Definition and treatment approach of non-criteria clinical manifestations of antiphospholipid syndrome.

Authors:  Ayten Yazıcı
Journal:  Eur J Rheumatol       Date:  2020-10

Review 5.  The antiphospholipid syndrome: from pathophysiology to treatment.

Authors:  Simone Negrini; Fabrizio Pappalardo; Giuseppe Murdaca; Francesco Indiveri; Francesco Puppo
Journal:  Clin Exp Med       Date:  2016-06-22       Impact factor: 3.984

6.  Kidney involvement in antiphospholipid syndrome - current diagnostic and management problems.

Authors:  Maria Majdan
Journal:  Reumatologia       Date:  2017-10-28

Review 7.  Renal Involvement in Antiphospholipid Syndrome.

Authors:  Alonso Turrent-Carriles; Juan Pablo Herrera-Félix; Mary-Carmen Amigo
Journal:  Front Immunol       Date:  2018-05-17       Impact factor: 7.561

8.  Lupus Nephritis with Coexistent Antiphospholipid Antibodies Associated Nephropathy: A Case Report and Literature Review.

Authors:  K Talari; U Anandh; A Patrick
Journal:  Indian J Nephrol       Date:  2018 Mar-Apr

9.  Renal protective effect of antiplatelet therapy in antiphospholipid antibody-positive lupus nephritis patients without antiphospholipid syndrome.

Authors:  Hironari Hanaoka; Harunobu Iida; Tomofumi Kiyokawa; Yukiko Takakuwa; Takahiro Okazaki; Hidehiro Yamada; Shoichi Ozaki; Kimito Kawahata
Journal:  PLoS One       Date:  2018-05-03       Impact factor: 3.240

Review 10.  Antiphospholipid Syndrome Nephropathy: From Pathogenesis to Treatment.

Authors:  Maria G Tektonidou
Journal:  Front Immunol       Date:  2018-05-31       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.